Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Soluble B7-H4 blood serum levels are elevated in women at high risk for preeclampsia in the first trimester, as well as in patients with confirmed preeclampsia

Item Type:Article
Title:Soluble B7-H4 blood serum levels are elevated in women at high risk for preeclampsia in the first trimester, as well as in patients with confirmed preeclampsia
Creators Name:Mach, P. and Nolte-Boenigk, L. and Droste, L. and Fox, L. and Frank, M. and Schmidt, B. and Herse, F. and Verlohren, S. and Wicherek, L. and Iannaccone, A. and Birdir, C. and Andrikos, D. and Kimmig, R. and Gellhaus, A. and Köninger, A.
Abstract:PROBLEM: B7-H4 negatively regulates T-cell-mediated immunity and might play an important role in preeclampsia (PE). Here, we have investigated the association between PE and maternal soluble B7-H4 (sB7-H4) serum levels and B7-H4 mRNA expression in the placenta. METHOD OF STUDY: Maternal serum levels of sB7-H4 were determined by enzyme-linked immunosorbent assay in women between 11 and 13 weeks' gestation with elevated risk for PE (n = 48) and women without elevated risk for PE (n = 47). In the third trimester, sB7-H4 serum levels (n = 166) and B7-H4 mRNA expression in the placenta (n = 54) were determined in women with early-onset PE, late-onset PE, fetal growth restriction (FGR), and in healthy controls. RESULTS: In the first trimester, significant higher levels of sB7-H4 were detected in women at elevated risk for PE compared to women without risk for PE (P < .0001). sB7-H4 has some predictive ability to identify cases with an elevated risk of developing PE with area under the curve (AUC) value of 0.88 (95% CI 0.8-0.94). Using a specificity of 90.0% led to a sensitivity of 47.9% and a threshold of 3.63 ng/mL. In the third trimester, the highest serum levels of sB7-H4 and B7-H4 mRNA expression in the placenta were observed in early-onset PE. Significant higher serum levels of sB7-H4 and B7-H4 mRNA expression in the placenta were observed in women with early-onset PE (P = .01 and P = .006, respectively) and late-onset PE (P = .03 and P = .004, respectively) compared to healthy controls, but not compared to FGR. CONCLUSION: sB7-H4 is involved in the regulation of immune tolerance in women with PE in the third trimester. In the first trimester of pregnancy, sB7-H4 might serve as a predictive immunological biomarker for women who are at elevated risk of developing PE.
Keywords:Immune Tolerance, Preeclampsia, sB7-H4
Source:American Journal of Reproductive Immunology
ISSN:1046-7408
Publisher:Wiley-Blackwell (Denmark)
Volume:80
Number:3
Page Range:e12988
Date:September 2018
Official Publication:https://doi.org/10.1111/aji.12988
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library